“Innovation Pharma is separated from the pack in a number of ways, including being Phase 3-ready and hitting the primary endpoint in the Phase 2 study by demonstrating that their oral rinse formulation was beneficial in preventing the onset of SOM in addition to key secondary endpoints, namely reducing the duration of SOM when it did develop. Most other pharmas developing drugs are focused on reducing duration, not prevention”
That article is extremely relative and is actually on iPix website blog.
Prevention for iPix at a higher rate and swish and spit vs 60 min IV.... That is why iPix feel they are going to be the leader in this BLUE SKY market. Big money for iPix
News 
Market Data 
Discover 
AI
